Introduction {#tca12573-sec-0001}
============

Radiotherapy is an essential tool for the management of thoracic tumors. However, radiation‐induced lung injury (RILI), the term generally used to describe damage to the lungs caused by exposure to ionizing radiation, is the main obstacle limiting dosage. Manifestations of RILI include early‐stage radiation pneumonitis (RP) and subsequent stage radiation pulmonary fibrosis (RPF).

Radiation pneumonitis typically occurs within three months after radiation therapy, and is pathologically characterized across diverse grades by numerous infiltrating inflammatory cells in the edema interval of broken alveolar and in the bronchus.[1](#tca12573-bib-0001){ref-type="ref"} RPF, considered a result of chronic lung damage, occurs at 6--24 months post‐radiotherapy, and includes irreversible corruption of the alveoli, activation of myofibroblasts, abnormal deposition of extracellular collagen matrix, and deregulated remodeling of lung tissue.[1](#tca12573-bib-0001){ref-type="ref"} Clinical data have demonstrated that the incidence of RILI ranges from 20.3% to 36.9%.[2](#tca12573-bib-0002){ref-type="ref"} However, only a few successful therapeutic strategies have been proposed, despite extensive research.

Mesenchymal stem cells (MSCs) have been well characterized and can be isolated from various tissues, such as bone marrow,[3](#tca12573-bib-0003){ref-type="ref"} adipose,[4](#tca12573-bib-0004){ref-type="ref"} umbilical cord,[5](#tca12573-bib-0005){ref-type="ref"} placenta,[6](#tca12573-bib-0006){ref-type="ref"} and circulatory vessel walls.[7](#tca12573-bib-0007){ref-type="ref"} Because of a number of functional advantages, including self‐proliferation, multi‐differentiation, injury foci chemotaxis, anti‐inflammation, and immunomodulation, this cell population has become a focus of research.[8](#tca12573-bib-0008){ref-type="ref"} MSC‐based therapies have been successfully used to repair tissue and several organs, including the lungs.[9](#tca12573-bib-0009){ref-type="ref"}

Based on accumulating evidence, MSC transplantation has been proposed as a potential therapeutic approach to address inflammatory diseases, such as RILI. Controversially, reports have also shown that MSCs actually enhance the progression of lung injuries characterized by inflammation and fibrosis. These contradictory results suggest that MSCs may have dual effects and that caution should be taken when using MSCs to treat RILI.

In this review, we present and discuss recent evidence of the double‐edged function of MSCs and provide comments on the prospects of these findings.

Evidence supporting the application of mesenchymal stem cells (MSCs) for the treatment of radiation‐induced lung injury (RILI) {#tca12573-sec-0002}
==============================================================================================================================

The use of MSCs in RILI models {#tca12573-sec-0003}
------------------------------

Reports of the therapeutic application of MSCs in RILI animal models have recently been published. Dong *et al.* confirmed that systemic infusion of human adipose tissue‐derived MSCs (AMSCs) ameliorated lung fibrosis in rats that received semi‐thoracic irradiation (15 Gy) by upregulating HGF and PGE2, while downregulating TNF‐α and TGF‐β1.[10](#tca12573-bib-0010){ref-type="ref"} Furthermore, several similar reports have demonstrated upregulation of IL‐10 and downregulation of IL‐1, IL‐6, and TNF‐α in murine serum, and downregulation of TGF‐β1, α‐smooth muscle actin (SMA), and type I collagen in irradiated murine lung tissues.[3](#tca12573-bib-0003){ref-type="ref"}, [11](#tca12573-bib-0011){ref-type="ref"}, [12](#tca12573-bib-0012){ref-type="ref"}, [13](#tca12573-bib-0013){ref-type="ref"} AMSCs have been shown to protect lung cells from apoptosis by regulating the expression of pro‐apoptotic and anti‐apoptotic mediators, including Bcl‐2, Bax, and caspase‐3.[3](#tca12573-bib-0003){ref-type="ref"}, [11](#tca12573-bib-0011){ref-type="ref"}, [12](#tca12573-bib-0012){ref-type="ref"}, [13](#tca12573-bib-0013){ref-type="ref"}

Wang *et al.* applied human umbilical cord blood‐derived MSCs (hUMSCs) to an acute RP animal model.[12](#tca12573-bib-0012){ref-type="ref"} The results indicated that hUMSCs have definite therapeutic effects on acute RP in rats.

Zhen *et al.* administered bone marrow‐derived mesenchymal stem cells (BMSCs) from male donor rats into female recipients in a model of pulmonary emphysema induced by irradiation and papain instillation.[14](#tca12573-bib-0014){ref-type="ref"} Emphysematous changes were ameliorated in rats that received BMSC infusions compared to rats that did not, revealing a protective mechanism of BMSC engraftment in the lungs, their differentiation into type II alveolar epithelial cells, and suppression of alveolar cell apoptosis. Similarly, Klein *et al.* treated whole thorax irradiated mice with allogeneic BMSCs or aorta‐derived MSCs.[15](#tca12573-bib-0015){ref-type="ref"} Irradiation induced endothelial cell damage, senescence of lung epithelial cells, and upregulation of invasion and inflammation‐promoting factors, while the MSCs antagonized this damage to resident cells as well as the resulting secretome changes and abrogated the metastasis‐promoting effects of thorax irradiation.

MSCs for acute lung injury (ALI) {#tca12573-sec-0004}
--------------------------------

Chemical agents, such as bleomycin, hydrochloric acid, and amiodarone, have been employed to establish acute lung injury (ALI) in animal models.[16](#tca12573-bib-0016){ref-type="ref"}, [17](#tca12573-bib-0017){ref-type="ref"} Using these animal models, allogeneic BMSCs have been shown to elicit anti‐inflammatory and pro‐healing properties. In fact, BMSCs were found to reduce circulating and in situ inflammatory cytokines, such as TGF‐β, PDGF‐A, PDGF‐B, and IGF‐1,[18](#tca12573-bib-0018){ref-type="ref"} and to protect against myelosuppression induced by bleomycin.[3](#tca12573-bib-0003){ref-type="ref"}, [13](#tca12573-bib-0013){ref-type="ref"} MSCs are also capable of inhibiting the proliferation of effector T lymphocytes and effectively induce T‐lymphocyte anergy by changing the secretome of T‐lymphocyte subsets.[19](#tca12573-bib-0019){ref-type="ref"}, [20](#tca12573-bib-0020){ref-type="ref"} Furthermore, BMSCs were observed to home to sites of tissue injury, where they differentiated into specific lung cell phenotypes.[13](#tca12573-bib-0013){ref-type="ref"} Recently, the beneficial effect of infused multi‐potent adult stem/progenitor cells has been explained by expression of the inflammatory modulating protein TNF‐α‐stimulated gene/protein‐6, which predominantly modulates the early inflammatory phase.[21](#tca12573-bib-0021){ref-type="ref"}

Lipopolysaccharide (LPS) extracted from pathogenic microorganisms, including *Escherichia coli* and *Pseudomonas aeruginosa* (*P. aeruginosa*), is often used as an endotoxin to induce ALI in animal models. BMSCs have been shown to home to and repair both intratracheal LPS‐induced intrapulmonary ALI and intravenous LPS/zymosan‐induced extra‐pulmonary ALI,[22](#tca12573-bib-0022){ref-type="ref"} while AMSCs have been found to exert therapeutic effects against *P. aeruginosa* pneumonia.[4](#tca12573-bib-0004){ref-type="ref"} It can be speculated that the protective mechanism involves inhibition of PGE2 production and improvements in phagocytosis and the bactericidal properties of macrophages.[4](#tca12573-bib-0004){ref-type="ref"} BMSCs have also been used successfully in an ovine model of severe acute respiratory distress syndrome (ARDS) caused by *P. aeruginosa* pneumonia. These cells not only improved oxygenation, but also decreased pulmonary edema.[13](#tca12573-bib-0013){ref-type="ref"}

Cobolt gamma‐ray radiation has been reported to inhibit the differentiation potential of BMSCs without significantly affecting their paracrine activity, cell proliferation, viability, or homing potential.[23](#tca12573-bib-0023){ref-type="ref"} Zhu *et al.* treated rats with smoke inhalation lung injuries using BMSCs and found that lung vascular endothelial injury and increased permeability were alleviated, predominantly as a result of enhanced angiogenesis, regulated by the notch signaling pathway.[23](#tca12573-bib-0023){ref-type="ref"}

To assess the safety of allogeneic BMSC administration in ARDS patients, a phase I clinical trial (NCT01775774) was performed using nine cases. No pre‐specified infusion‐associated events or treatment‐related adverse events were reported, demonstrating good tolerability of allogeneic BMSCs in moderate‐to‐severe ARDS patients.[24](#tca12573-bib-0024){ref-type="ref"} Similar results were obtained in a second clinical trial (NCT01902082) in which ARDS patients were treated with allogeneic AMSCs or a placebo. However, in this study, AMSCs failed to exhibit any significantly beneficial clinical effects other than a reduction in the serum levels of surfactant protein‐D.[25](#tca12573-bib-0025){ref-type="ref"} In contrast, Chang *et al.* reported the successful clinical application of hUMSCs to treat ARDS in a single patient.[26](#tca12573-bib-0026){ref-type="ref"}

Gene‐modified MSCs for the treatment of ALI {#tca12573-sec-0005}
-------------------------------------------

Because MSCs are capable of homing to sites of injury, they are often employed as cellular vehicles for gene delivery and have been developed to treat various diseases, including ALI.[27](#tca12573-bib-0027){ref-type="ref"}

Angiotensin II, which can be degraded by ACE2, plays an important role in the process of endothelial dysfunction in ALI, and ACE2 deficiency enhances lung injuries in mice.[28](#tca12573-bib-0028){ref-type="ref"} When infused into ACE2^−/y^ mice, BMSCs^ACE2+^ (transfected with the *ACE2* gene) improved lung histopathology but had additional anti‐inflammatory effects, reduced pulmonary vascular permeability, improved endothelial barrier integrity, and normalized lung endothelial nitric oxide synthase expression.[5](#tca12573-bib-0005){ref-type="ref"}, [28](#tca12573-bib-0028){ref-type="ref"}, [29](#tca12573-bib-0029){ref-type="ref"}, [30](#tca12573-bib-0030){ref-type="ref"}, [31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"} Furthermore, BMSC^ACE2+^ downregulated pulmonary expression of ICAM‐1, VCAM‐1, TNF‐α, and IL‐6, and was more effective in treating bleomycin‐induced ALI in a murine model than ACE2 or hUMSC alone.[5](#tca12573-bib-0005){ref-type="ref"}, [28](#tca12573-bib-0028){ref-type="ref"}, [30](#tca12573-bib-0030){ref-type="ref"}, [31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"} Interestingly, some factors were decreased in BMSC^ACE2+^‐injected mice, including malondialdehyde, oxidized glutathione, TNF‐α, IFN‐γ, TGF‐β, IL‐1, IL‐2, IL‐6, collagen type 1, MMPs, TIMPs, and hydroxyproline, while other factors were increased, including superoxide dismutase, glutathione, ACE2, and IL‐10.[30](#tca12573-bib-0030){ref-type="ref"}, [31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"}

TGF‐β, which is recognized as both a fibrogenic and inflammatory cytokine, plays critical roles in various pathophysiological processes and is an independent predictor of RILI.[35](#tca12573-bib-0035){ref-type="ref"} Following transfection with the TGF‐β type II receptor gene, BMSC^TGFBR+^ migrated into injured lungs and obviously alleviated lung injuries in mice challenged with thoracic irradiation.[31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"} These results were further confirmed by concentration of factor assays, such as malondialdehyde, hydroxyproline, CTGF, and α‐SMA.[31](#tca12573-bib-0031){ref-type="ref"} Furthermore, BMSC^TGFBR+^ adopted the characteristics of alveolar type II cells at the injury site.[31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"}

FGF‐2 is a multifunctional growth factor found in different tissues and cell types.[36](#tca12573-bib-0036){ref-type="ref"} BMSC^FGF2+^ expressing exogenous *FGF2* following lentivirus‐mediated transduction was used in an LPS‐induced murine ALI model. Compared to groups treated with BMSCs alone, LPS‐induced lung injury was alleviated in the group treated with BMSCs^FGF2+^. Furthermore, the histopathological index of lung injury was improved and levels of inflammatory cytokines were reduced.[32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"}

HGF plays mitogenic, morphogenic, and anti‐apoptotic roles in a variety of cells, including most epithelial and endothelial cells.[27](#tca12573-bib-0027){ref-type="ref"} HGF enhances lung regeneration and inhibits lung fibrosis.[27](#tca12573-bib-0027){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"} Wang *et al*. reported the significant therapeutic effect of BMSC^HGF+^ in an RILI murine model mediated by reducing the secretion of pro‐inflammatory cytokines, including TNF‐α, IFN‐γ, IL‐6, and ICAM‐1, and pro‐fibrosis factors, including TGF‐β, Col‐1α1, and Col‐3α1, while increasing the expression of anti‐inflammatory cytokines, including IL‐10. BMSC^HGF+^ was found to promote the proliferation of lung epithelial cells, thus protecting against apoptosis and stimulating a significant increase in the expression of endogenous HGF and its receptor, c‐Met.[33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"}

CXCR4, also known as fusin or CD184, is involved in MSC mobilization, but is only expressed on the surface of a small proportion of MSCs. The lack of CXCR4 expression on MSCs may underlie their low homing efficiency toward injured tissues.[37](#tca12573-bib-0037){ref-type="ref"}, [38](#tca12573-bib-0038){ref-type="ref"} Using a LPS‐induced ALI murine model, Yang *et al*. showed that BMSC^CXCR4+^ increased the efficiency of BMSC mobilization to injury sites. Therefore, BMSCs^CXCR4+^ modified to overexpress CXCR4 improved the therapeutic potential of these cells for the treatment of ALI by increasing self‐renewal, homing, and epithelial differentiation.[37](#tca12573-bib-0037){ref-type="ref"}, [39](#tca12573-bib-0039){ref-type="ref"}

Del‐1 is another critical factor involved in cell migration and infiltration. This molecule inhibits the function of the major leukocyte adhesion receptor LFA‐1, which prevents leukocyte adhesion to the endothelium.[34](#tca12573-bib-0034){ref-type="ref"} Zhao *et al.* showed that treatment of LPS‐induced ALI mice with BMSCs^Del1+^ (allogeneic Del‐1‐overexpressing BMSCs) significantly decreased the severity of endotoxin‐induced lung injury and inflammatory cytokine levels.[34](#tca12573-bib-0034){ref-type="ref"}

"Cell‐free" treatments for ALI {#tca12573-sec-0006}
------------------------------

In addition to MSCs themselves, MSC‐derived extracellular vesicles have also been extensively investigated for their paracrine effect.[40](#tca12573-bib-0040){ref-type="ref"} Numerous biological functions of MSCs have been demonstrated as a result of the paracrine effects of extracellular vesicles.[40](#tca12573-bib-0040){ref-type="ref"}, [41](#tca12573-bib-0041){ref-type="ref"}, [42](#tca12573-bib-0042){ref-type="ref"} According to their size, the vesicles are classified as exosomes (40--120 nm) and microvesicles (MVs; 200--1000 nm).

Microvesicles are circular fragments of membrane released from the endosomal compartment as exosomes or shed from the surface membrane.[43](#tca12573-bib-0043){ref-type="ref"} Because the central mechanism of cell‐to‐cell communication involves the packaging of bioactive factors in MVs, it was thought that the therapeutic potential of MSCs was largely mediated by MVs released from intracellular endosomes.[43](#tca12573-bib-0043){ref-type="ref"}, [44](#tca12573-bib-0044){ref-type="ref"} When administered intratracheally in endotoxin‐induced ALI mice, MVs improved pulmonary edema and lung protein permeability, reduced neutrophil influx, and decreased MIP‐2 levels in bronchoalveolar lavage fluid, demonstrating a reduction in inflammation. However, the therapeutic effects were partially eliminated if MVs were released from low expression KGF BMSCs, suggesting that KGF plays an important role in the underlying mechanism.[42](#tca12573-bib-0042){ref-type="ref"} As highlighted by Sdrimas *et al.*, despite accumulating evidence of the use of MSC MVs in lung disease, very little is known about the underlying mechanism.[43](#tca12573-bib-0043){ref-type="ref"}

In recent years, evidence of the therapeutic effect of MSC conditioned medium (CM) on lung injuries has been reported.[31](#tca12573-bib-0031){ref-type="ref"}, [45](#tca12573-bib-0045){ref-type="ref"} BMSC CM has been shown to attenuate lung fibrosis of bleomycin‐challenged rats in terms of lung inflammation, fibrotic scores, collagen deposition, and cell apoptosis.[45](#tca12573-bib-0045){ref-type="ref"} Thus, the paracrine capability of MSCs and their anti‐inflammatory and anti‐fibrotic mechanisms are now recognized.[27](#tca12573-bib-0027){ref-type="ref"}, [46](#tca12573-bib-0046){ref-type="ref"}

Evidence supporting the detrimental effects of MSCs in RILI {#tca12573-sec-0007}
===========================================================

Pro‐fibrotic cells derived from MSCs {#tca12573-sec-0008}
------------------------------------

### Fibrocytes {#tca12573-sec-0009}

Fibrocytes are circulating BMSCs with unique growth characteristics and surface phenotype. This cell type can differentiate into fibroblasts and myofibroblasts following entry into the tissues.[47](#tca12573-bib-0047){ref-type="ref"} Myofibroblasts in the tumor stroma, known as cancer‐associated fibroblasts, participate in the support of tumor growth, angiogenesis, metastasis, and therapy resistance.[48](#tca12573-bib-0048){ref-type="ref"} Clinical biopsies have shown that fibrocytes exist in the lungs of most idiopathic pulmonary fibrosis (IPF) patients (8/9). Furthermore, the risk of pulmonary fibrosis (PF) increases with the number of fibrocytes in the lungs, although the underlying mechanism is unclear.[49](#tca12573-bib-0049){ref-type="ref"}, [50](#tca12573-bib-0050){ref-type="ref"}, [51](#tca12573-bib-0051){ref-type="ref"}, [52](#tca12573-bib-0052){ref-type="ref"}, [53](#tca12573-bib-0053){ref-type="ref"} Fibrocytes are believed to be involved in the pathogenesis of several fibrotic disorders affecting the lungs, liver, kidney, and other organs. Furthermore, they have been implicated as potential biomarkers that are easily detected and quantified from peripheral blood samples.[54](#tca12573-bib-0054){ref-type="ref"}

Pulmonary fibrosis was originally thought to be mediated solely by resident lung fibroblasts.[1](#tca12573-bib-0001){ref-type="ref"} However, increasing data indicates that intrapulmonary recruitment of fibrocytes is directly correlated with increased collagen deposition in the lungs. Phillips *et al*. identified a population of human CD45^+^/Col I^+^/CXCR4^+^ circulating fibrocytes that migrated to sites of lung injury in response to CXCL12 signaling in models of bleomycin‐induced PF.[49](#tca12573-bib-0049){ref-type="ref"}, [50](#tca12573-bib-0050){ref-type="ref"}, [51](#tca12573-bib-0051){ref-type="ref"}, [52](#tca12573-bib-0052){ref-type="ref"}, [53](#tca12573-bib-0053){ref-type="ref"}, [55](#tca12573-bib-0055){ref-type="ref"} Mehrad *et al.* reported that fibrocyte recruitment is mediated by the CXCL12/CXCR4 axis in vitro, and revealed high CXCL12 levels in the plasma and injured lungs of patients with fibrotic interstitial lung disease.[56](#tca12573-bib-0056){ref-type="ref"} There were significantly more circulating peripheral blood fibrocytes in patients with fibrotic interstitial lung disease than in healthy controls. Furthermore, CXCR4, the predominant chemokine receptor, has been identified on human fibrocytes, and has been found to mediate the influx of these cells into the lung during PF. Regulation of CXCR4 is reported to be mediated by hypoxia and growth factors, such as PDGF, via the PI3‐kinase and mTOR signaling pathways.[50](#tca12573-bib-0050){ref-type="ref"}, [57](#tca12573-bib-0057){ref-type="ref"}

### Lung hematopoietic progenitor cells {#tca12573-sec-0010}

Green fluorescent protein (GFP) bone marrow‐chimera mice were employed in studies by Nakashima *et al.* to elucidate the roles of bone marrow‐derived cells in bleomycin‐induced PF.[51](#tca12573-bib-0051){ref-type="ref"} The results showed an increase in high‐GFP expressing cells (GFP^hi^) in the fibrotic lungs, with phenotypic characteristics of CD11c^+^ dendritic cells and macrophages. CM from these cells was chemotactic for fibroblasts from fibrotic lungs in vitro, and adoptive transfer of GFP^hi^ exacerbated disease in a bleomycin‐induced mouse model of PF. It was also observed that GFP^hi^ differentiated from lung hematopoietic progenitor cells (LHPCs) (c‐Kit^+^/Sca1^−^/Lin^−^ and GFP^+^), with numbers increasing rapidly in response to bleomycin treatment. These findings indicated that LHPCs represent a novel therapeutic approach for chronic fibrotic lung diseases.

### ABCG2^+^ MSCs {#tca12573-sec-0012}

Adult lung tissue contains a population of perivascular ABCG^2+^ MSCs, which are proven precursors of myofibroblasts distinct from NG2 pericytes. Marriott *et al.* found that resident lung MSCs were increased in human PF samples.[52](#tca12573-bib-0052){ref-type="ref"} ABCG^2+^ MSCs were found to increase in number and localize to the interstitial areas during fibrotic microvessel remodeling in bleomycin‐challenged mice. Furthermore, these cells responded to bleomycin treatment by expressing pro‐fibrotic genes. Thus, ABCG^2+^ lung MSCs are implicated as a novel cell population that contributes to detrimental myofibroblast‐mediated remodeling during PF.

Summary and prospects {#tca12573-sec-0013}
=====================

Despite the considerable number of studies that have been performed, the clinical management of RILI using a stem cell approach requires further investigation. Based on the reports of studies focusing on the effects of MSCs in RILI, ALI, ARDS, and chronic obstructive pulmonary disease models (as shown in Table [1](#tca12573-tbl-0001){ref-type="table-wrap"}), we can conclude that:There have been no serious adverse events reported in any pre‐clinical or clinical study of MSC reported to date.MSCs shown to elicit a therapeutic potential in RILI were predominantly from allogeneic donor tissues, such as AMSCs, BMSCs, and UMSCs.The majority of MSCs had a deleterious effect by promoting RILI and other endogenous forms of the lung, such as fibrocytes, LHPCs, and BMSCs^ABCG2+^. These cell populations produce detrimental pro‐inflammatory and pro‐fibrotic effects under the regulation of CXCL12/CXCR4 and Wnt/β‐catenin signaling.The data described in this report is preliminary, obtained from non‐RILI animal models, such as bleomycin‐induced, LPS‐induced, and HCl‐induced lung injuries.

###### 

Different types of stem cells used in lung injury models produce various effects

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                     SCs          Origins of SCs   Biomarkers                                                                                                          Genemodification   Animal models                             Treatment phases                                     Effect of SC on lung injury
  ------------------------------------------------------------------------- ------------ ---------------- ------------------------------------------------------------------------------------------------------------------- ------------------ ----------------------------------------- ---------------------------------------------------- -----------------------------
  Mao *et al.* 2015[4](#tca12573-bib-0004){ref-type="ref"}                  ASC          Allogeneic       CD34(+), CD45(+), CD90(+), CD105(+)                                                                                 ---                *P. aeruginosa* pneumonia                 1 hour after lung injury                             Therapeutic

  Min *et al.* 2015[5](#tca12573-bib-0005){ref-type="ref"}                  hUMSC        Heterogenic      CD29(+), CD44(+), CD105(+); CD34(−), CD45(−), CD86(−)                                                               ACE2               Bleomycin‐induced lung injury             ---                                                  Therapeutic

  Zhao *et al.* 2014[6](#tca12573-bib-0006){ref-type="ref"}                 PMSC         Heterogenic      CD29(+), CD44(+), CD73(+), CD90(+), CD105(+), CD14(−), CD19(−), CD34(−), CD45(−), HLA‐DR(−)                         ---                Bronchiolitis obliterans                  3 days after lung injury                             Therapeutic

  Dong *et al.* 2015[10](#tca12573-bib-0010){ref-type="ref"}                ASC          Heterogenic      CD73(+), CD90(+), CD105(+); CD11b(−), CD19(−), CD34(−), CD45(−), HLA‐DR(−)                                          ---                Radiation‐induced pulmonary fibrosis      2 hours after lung injury                            Therapeutic

  Jiang *et al.* 2015[11](#tca12573-bib-0011){ref-type="ref"}               ASC          Allogeneic       CD29(+), CD44(+); CD11b(−), CD45(−)                                                                                 ---                Acute radiation‐induced lung injury       2 hours after lung injury                            Therapeutic

  Wang *et al.* 2014[12](#tca12573-bib-0012){ref-type="ref"}                hUMSC        Heterogenic      CD29(+), CD34(+), CD44(+), CD73(+), CD90(+), CD105(+); CD45(−)                                                      ---                Radiation pneumonitis                     Prevention group: 24 hours before lung injury;\      Therapeutic
                                                                                                                                                                                                                                                                                           Treatment group: 24 hours after lung injury          

  Asmussen *et al.* 2014[13](#tca12573-bib-0013){ref-type="ref"}            hUMSC        Heterogenic      ---                                                                                                                 ---                Bacterial pneumonia (ARDS)                1 hour after lung injury                             Therapeutic

  Zhen *et al.* 2008[14](#tca12573-bib-0014){ref-type="ref"}                BMSC         Allogeneic       ---                                                                                                                 ---                Papain‐induced pulmonary emphysema        1 day after lung injury                              Therapeutic

  Zickri *et al.* 2014[16](#tca12573-bib-0016){ref-type="ref"}              hUMSC        Heterogenic      CD45(+), CD105(+), CD133(+)                                                                                         ---                Amiodarone‐induced lung injury            4 weeks after lung injury                            Therapeutic

  Zhao *et al.* 2008[18](#tca12573-bib-0018){ref-type="ref"}                BMSC         Allogeneic       ---                                                                                                                 ---                Bleomycin‐induced lung injury             12 hours after lung injury                           Therapeutic

  Liu *et al.* 2015[22](#tca12573-bib-0022){ref-type="ref"}                 Mouse BMSC   Allogeneic       ---                                                                                                                 ---                Acute lung injury                         4 hours after lung injury                            Therapeutic

  Zhu *et al.* 2015[23](#tca12573-bib-0023){ref-type="ref"}                 Rat BMSC     Allogeneic       CD45(+), VEGF(+), bFGF(+), CD44(−), CD90(−)                                                                         ---                Smoke‐induced lung injury                 ---                                                  Therapeutic

  He *et al.* 2014[29](#tca12573-bib-0029){ref-type="ref"}                  Mouse BMSC   Allogeneic       ACE2(+), ß‐actin(+)                                                                                                 ACE2               LPS‐induced lung injury                   4 hours after lung injury                            Therapeutic

  Liu *et al.* 2014[30](#tca12573-bib-0030){ref-type="ref"}                 hUMSC        Heterogenic      CD29(+), CD44(+), CD105(+); CD34(−), CD45(−), CD86(−)                                                               ACE2               Acute lung ischemia‐ reperfusion injury   45 minutes, 6 hours and 24 hours after lung injury   Therapeutic

  Xue *et al.* 2013[31](#tca12573-bib-0031){ref-type="ref"}                 Mouse BMSC   Allogeneic       Sca‐1(+), CD29(+), CD44(+), sTβR(+); CD11b(−), CD31(−), CD45(−), CD117(−)                                           sTβR               Radiation‐induced lung injury             Zero days or 14 days after radiation                 Therapeutic

  Zhao *et al.* 2015[32](#tca12573-bib-0032){ref-type="ref"}                Mouse BMSC   Allogeneic       CD73(+), CD90(+), CD105(+), CD106(+), FGF2(+); CD11b(−), CD14(−), CD34(−), CD45(−),                                 FGF2               LPS‐induced lung injury                   1 hour after lung injury                             Therapeutic

  Wang *et al.* 2013[33](#tca12573-bib-0033){ref-type="ref"}                hUMSC        Heterogenic      CD29(+), CD73(+), CD166(+), HGF(+), HLAABC(+); CD31(−), CD34(−), CD45(−), HLA‐DR(−)                                 HGF                Radiation‐induced lung injury             6 hours after lung injury                            Therapeutic

  Zhao *et al*. 2014[34](#tca12573-bib-0034){ref-type="ref"}                Mouse BMSC   Allogeneic       CD73(+), CD90(+), CD105(+), CD106(+); CD11b(−), CD14(−), CD34(−), CD45(−)                                           DEL‐1              LPS‐induced lung injury                   1 hour after lung injury                             Therapeutic

  Yang *et al.* 2015[37](#tca12573-bib-0037){ref-type="ref"}                BMSC         Allogeneic       CD29(+), CD34(+), CD45(+), CD90(+), VCAM‐1(+), ICAM‐1(+)                                                            CXCR4              LPS‐induced lung injury                   1 hour after lung injury                             Therapeutic

  Hayes *et al.* 2015[58](#tca12573-bib-0058){ref-type="ref"}               hUMSC        Heterogenic      ---                                                                                                                 ---                Ventilator‐induced lung injury            15--30 minutes after lung injury                     Therapeutic

  Liu *et al.* 2014[59](#tca12573-bib-0059){ref-type="ref"}                 hUMSC        Heterogenic      CD49c(+), CD49d(+), CD49e(+), CD49f(+), CD73(+), CD90(+), CD105(+); CD14(−), CD19(−), CD34(−), CD45(−), HLA‐DR(−)   ---                Hyperoxia‐induced neonatal lung injury    On postnatal day 5                                   Therapeutic

  Wilson *et al.* 2015[24](#tca12573-bib-0024){ref-type="ref"}              Human BMSC   Allogeneic       ---                                                                                                                 ---                Moderate‐to‐severe ARDS                   120 hours after lung injury                          Therapeutic

  Zheng *et al.* 2014[25](#tca12573-bib-0025){ref-type="ref"}               Human ASCs   Allogeneic       CD73(+), CD90(+),\                                                                                                  ---                ARDS patients                             1--48 hours of enrollment                            Therapeutic
                                                                                                          CD105(+); CD34(−), CD45(−), (HLA)‐DR(−)                                                                                                                                                                                               

  Chang *et al.* 2014[26](#tca12573-bib-0026){ref-type="ref"}               hUMSC        Allogeneic       CD29(+), CD44(+), CD73(+), CD105(+), CD166(+); CD14(−), CD34(−), CD45(−), HLA‐DR(−)                                 ---                ARDS patient                              On the 114th HD                                      Therapeutic

  Andersson‐Sjoland *et al.* 2008[49](#tca12573-bib-0049){ref-type="ref"}   Fibrocytes   Autologous       CXCR4(+), proly l‐4‐hydroxylase(+), CD34(+), SMA(+), CD45RO(+)                                                      ---                IPF patient                               ---                                                  Deleterious

  Strieter *et al.* 2009[50](#tca12573-bib-0050){ref-type="ref"}            Fibrocytes   Autologous       CD45(+), collagen I(+), CXCR4(+)                                                                                    ---                Bleomycin‐induced pulmonary fibrosis      ---                                                  Deleterious

  Nakashima *et al*. 2013[51](#tca12573-bib-0051){ref-type="ref"}           LHPC         Allogeneic       CD11c(+), CD45(+), MHC‐II(+), F4/80(+), CXCR4(+); CD11b(−), CD34(−), Sca1(−), c‐Kit(−), Ly6c(−), Col 1(−)           ---                Bleomycin‐induced pulmonary fibrosis      2 days after lung injury                             Therapeutic

  Marriot *et al.* 2014[52](#tca12573-bib-0052){ref-type="ref"}             Mouse MSC    Autologous       ABCG2(+), CD44(+), CD73(+), CD105(+), CD106(+), Scal(+); c‐kit(−), CD14(−), CD45(−)                                 ---                Bleomycin‐induced lung injury             Inflammatory phase post‐injury                       Deleterious

  Antoniou *et al.* 2010[60](#tca12573-bib-0060){ref-type="ref"}            Mouse BMSC   Autologous       CD29(+), CD44(+), CD73(+), CD90(+), CD105(+), CD146(+); CD34(−), CD45(−)                                            ---                IPF patient                               ---                                                  Deleterious

  Xu *et al.* 2007[61](#tca12573-bib-0061){ref-type="ref"}                  Mouse BMSC   Autologous       CD44(+), CD105(+), CXCR4(+); CD11b(−), CD45(−)                                                                      ---                Bleomycin‐induced lung injury             1, 3, 7, and 14 days after lung injury               Deleterious

  Sun *et al.* 2014[62](#tca12573-bib-0062){ref-type="ref"}                 BMSC         Allogeneic       CD29(+), CD44(+), CD73(+), CD90(+); CD11b(−), CD34(−), CD45(−), CD79(−), CD133(−)                                   ---                HCl‐induced acute lung injury             24 hours after lung injury                           Therapeutic
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ARDS, acute respiratory distress syndrome; ASC, adipose tissue‐derived mesenchymal stem cells; BMSC, bone marrow‐derived mesenchymal stem cells; HD, hospital day; hUMSC, human mesenchymal stem cells; HUMSC, human umbilical cord mesenchymal stem cells; IPF, idiopathic pulmonary fibrosis; LHPC, lung hematopoietic progenitor cells; LPS, lipopolysaccharide; PMSC, placenta‐derived human mesenchymal stem cells; sTβR, TGF‐β type II receptor.

However, several points remain unresolved, and these are discussed as follows (Table [1](#tca12573-tbl-0001){ref-type="table-wrap"}).

Issues of cell selection {#tca12573-sec-0014}
------------------------

Dong *et al.* proposed that AMSCs are beneficial for RILI, while Sun *et al.* demonstrated that BMSCs are not; however, whether AMSCs are more effective for this purpose than BMSCs remains to be confirmed.[10](#tca12573-bib-0010){ref-type="ref"}, [62](#tca12573-bib-0062){ref-type="ref"} Wang *et al.* demonstrated that infusion of hUMSCs improved RILI.[12](#tca12573-bib-0012){ref-type="ref"} Shu *et al.* reported that administration of BMSCs promoted lung fibrosis by increasing the number of myofibroblasts.[53](#tca12573-bib-0053){ref-type="ref"} These conflicting findings may be explained by differences between the studies. Regarding MSC preparation methods, Dong *et al.* used CD73, CD90, and CD105 as cell‐specific markers, while Wang *et al.* used CD29 and CD44 in addition to CD73, CD90, and CD105.[10](#tca12573-bib-0010){ref-type="ref"}, [12](#tca12573-bib-0012){ref-type="ref"} Sun *et al.* used CD29, CD44, CD73, and CD90 and Marriott *et al.* used ABCG2.[52](#tca12573-bib-0052){ref-type="ref"}, [62](#tca12573-bib-0062){ref-type="ref"} In contrast, Shu *et al.* used GFP‐positive expression as the only marker of BMSCs.[53](#tca12573-bib-0053){ref-type="ref"} These different MSC selection methods would result in distinct effects on lung injuries; thus, we hypothesize that a more beneficial MSC population exists within the mixed population of MSCs infused, and that the different proportions of this beneficial MSC population in the total population of MSCs may lead to diverse effects on RILI and other lung injuries. However, the identification and characterization of the beneficial MSC population remains a challenge.

Issues of phase selection {#tca12573-sec-0015}
-------------------------

The pathophysiological process of RILI is composed of several stages/phases. Foskett *et al.* described the toxic effects exerted by bleomycin as "damage/necrosis of the alveolar epithelium, tissue edema, inflammatory cell infiltration, and pulmonary fibrosis."[21](#tca12573-bib-0021){ref-type="ref"} Royce *et al.* concluded that inflammatory cell infiltration, cytokine release, epithelial damage, airway/lung remodeling, and fibrosis are all central features of inflammatory lung disorders.[63](#tca12573-bib-0063){ref-type="ref"} However, Graves *et al.* considered that the process of RILI has three phases: injury, inflammation, and repair.[1](#tca12573-bib-0001){ref-type="ref"} Based on the findings of this review, we believe that MSCs exhibit therapeutic effects primarily in the inflammation phase.[3](#tca12573-bib-0003){ref-type="ref"}, [10](#tca12573-bib-0010){ref-type="ref"}, [11](#tca12573-bib-0011){ref-type="ref"}, [12](#tca12573-bib-0012){ref-type="ref"}, [13](#tca12573-bib-0013){ref-type="ref"} While some MSCs seem to exert detrimental effects during the repair phase in RILI,[49](#tca12573-bib-0049){ref-type="ref"}, [50](#tca12573-bib-0050){ref-type="ref"}, [51](#tca12573-bib-0051){ref-type="ref"}, [52](#tca12573-bib-0052){ref-type="ref"}, [53](#tca12573-bib-0053){ref-type="ref"}, [55](#tca12573-bib-0055){ref-type="ref"} we conclude that administration of MSCs in different phases is likely to result in distinct therapeutic outcomes; however, more research is necessary.

Issues of gene modification in MSCs {#tca12573-sec-0016}
-----------------------------------

Some reports claim that modifying certain genes in the administered MSCs can improve outcomes in patients with RILI or other lung injuries,[5](#tca12573-bib-0005){ref-type="ref"}, [28](#tca12573-bib-0028){ref-type="ref"}, [29](#tca12573-bib-0029){ref-type="ref"}, [30](#tca12573-bib-0030){ref-type="ref"}, [31](#tca12573-bib-0031){ref-type="ref"}, [32](#tca12573-bib-0032){ref-type="ref"}, [33](#tca12573-bib-0033){ref-type="ref"}, [34](#tca12573-bib-0034){ref-type="ref"} while others have shown contradictory data.[37](#tca12573-bib-0037){ref-type="ref"}, [39](#tca12573-bib-0039){ref-type="ref"} However, all conclude that modification of some genes significantly alters the activity and bio‐behavior of the administered MSCs. Identification of the genes that should be changed in MSCs to achieve optimal results is essential. The potential effects of multiple gene modifications and the optimal method of gene modification are also critical issues that warrant further investigation.

Overall, investigation into the effect of MSC transplantation on RILI and other lung injuries has made good progress in recent years. Some of the mechanisms involved have become clearer and MSCs are already being evaluated in clinical trials. However, more questions are likely to arise as advances are made. The role of MSCs as a sword or an accomplice in RILI remains unresolved and more consistent and comparable research is necessary for further clarification that may lead to the development of successful treatment strategies.
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